Diagnostics Key Benefits
Aptamer Diagnostics Ltd is committed to working with our partners to bring aptamer-based diagnostic products to the market.
We work with R&D and academic partners on collaborative diagnostic development projects and with industry on contract development projects.
- APTA-DX has a technically superior approach to aptamer development.
- We use a proprietary, fully automated aptamer selection process, which means that better aptamers are delivered to the customer faster than the competing technologies.
- We deliver the optimised binder, the minimum functional aptamer fragment, (OptimerTM) as standard and is cost-effective.
- Our evidence-based approach, where individual aptamers are isolated following proof of binding at the pool level means you only spend your money where this is likely to be successful.
- Our approach is particularly suited for applications where:
- You have tried to make monoclonals in the past and failed.
- The target antigen may be in a cross-linked, fixed form.
- For small molecules, where our novel, patented “gain of signal” assay format boosts sensitivity.